NeoGenomics (NEO) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Stay long AI-capex winners into the peak, Stifel says despite bubble fears
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
NeoGenomics Reports 18% Revenue Growth and Strong Gains in Adjusted EBITDA
July 23, 2015 7:01 AM EDTFT. MYERS, Fla., July 23, 2015 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2015.
Second Quarter 2015 Highlights:
18% increase in consolidated revenue 9% growth in base(1) revenue despite $2.1 million reduction in FISH reimbursement 21% growth in base(1) test volume despite FISH insourcing by one large client Record low $215 Avg Cost per Test in base(1) business 300 basis point expansion in gross margin from 41.4% in... More